United States Drug Patent 6,239,180: Claim Scope, Expiration, Qutenza Coverage, and Patent Landscape

U.S. Patent No. 6,239,180 covers a high-concentration capsaicin transdermal patch for treating human neuropathic pain. Its independent claim requires a skin-adherent reservoir patch containing more than about 5% and up to 10% capsaicin or a capsaicin analog, with one administration providing relief for at least several weeks. The patent issued on May 29, 2001, from an application filed November 4, 1998, and its ordinary U.S. patent term expired on November 4, 2018.[1]

The patent is closely associated with the therapeutic concept later commercialized as Qutenza, an 8% capsaicin topical system. Patent 6,239,180 no longer creates an enforceable U.S. exclusion right. It remains relevant as prior art, as a historical foundation for high-dose capsaicin therapy, and as a reference point for analyzing later formulation, device, manufacturing, and method-of-use patents.

What does U.S. Patent 6,239,180 protect?

The patent protects a combination of structural and therapeutic limitations rather than capsaicin treatment in the abstract.

Limitation	Required scope
Patient	Human patient
Disease	Neuropathic pain
Delivery system	Skin-adherent patch
Patch structure	Reservoir containing a therapeutic formulation
Delivery mode	Continuous provision of formulation to the skin surface
Active ingredient	Capsaicin or capsaicin analog
Concentration	Greater than about 5% through 10% by weight
Clinical result	A single administration provides significant relief for at least several weeks

The core claim is therefore narrower than a claim covering any topical capsaicin product. A product must satisfy the patch, reservoir, concentration, patient, disease, delivery, and duration limitations together.

The claim also has a functional limitation: the single application must provide “significant relief” for “at least several weeks.” Those terms would ordinarily be interpreted in light of the patent specification, disclosed clinical data, and the knowledge of a person skilled in pain therapy and transdermal drug delivery.

How broad is claim 1 of Patent 6,239,180?

Claim 1 is a combination claim with several potential points of limitation.

Patch and reservoir requirement

The product must be a skin-adherent patch containing a reservoir. A simple cream, gel, ointment, liquid, spray, or physician-applied formulation would not inherently satisfy this limitation.

The reservoir language can cover a drug-containing matrix or compartment that continuously presents the formulation to the skin. The claim does not expressly require a separate backing layer, rate-controlling membrane, adhesive border, or defined application area.

High-concentration capsaicin requirement

The concentration range is greater than approximately 5% to 10% by weight. Claim 4 narrows this to approximately 7.5% to 10% by weight.

An 8% capsaicin product falls within both claim 1 and claim 4, assuming the other limitations are satisfied. A formulation containing exactly 5% capsaicin would raise a claim-construction issue because claim 1 requires a concentration greater than about 5%. A formulation above 10% would fall outside the literal concentration range in claims 1 and 4, subject to any applicable doctrine-of-equivalents analysis.

The term “total concentration” can be important where a formulation contains capsaicin together with one or more capsaicin analogs. The claim appears directed to the aggregate concentration of the active capsaicinoid component or components, not merely the concentration of naturally occurring capsaicin.

Neuropathic pain and treatment result

The claim requires treatment of neuropathic pain in a human. It does not expressly limit the disease to postherpetic neuralgia, diabetic peripheral neuropathy, HIV-associated neuropathy, or another named condition.

The several-week relief requirement is a material limitation. A patch that provides only short-term analgesia could avoid literal infringement even if its capsaicin concentration and physical construction were otherwise similar.

What do claims 2 through 5 add?

Claims 2 through 5 narrow claim 1 in different ways.

Claim	Added limitation	Commercial significance
2	Treatment follows effective anesthesia that blocks afferent nerve fibers	Links high-dose capsaicin treatment to pre-application anesthesia
3	A second patch delivers anesthetic in an amount effective to block afferent nerve fibers	Narrows claim 2 to a patch-based anesthetic component
4	Capsaicin concentration is approximately 7.5% to 10% by weight	Directly covers an 8% product
5	The active is capsaicin rather than an unspecified analog	Removes analog breadth

Claim 2: anesthesia before capsaicin treatment

Claim 2 requires effective anesthesia before application of the capsaicin formulation. The anesthesia must block afferent nerve fibers, not merely provide comfort or reduce superficial irritation.

This limitation reflects the known tolerability problem associated with high-concentration capsaicin. The treatment can cause substantial burning and pain during or shortly after application. Qutenza labeling instructs healthcare professionals to use topical anesthetic before application and to manage treatment-related discomfort.[2]

Claim 3: a second anesthetic patch

Claim 3 is narrower than the commercial treatment protocol if the anesthetic is supplied as a cream, gel, injection, or other non-patch product. The claim requires a second patch capable of delivering the anesthetic.

The phrase in the supplied claim text stating that the anesthetic patch is used “to the side effects” of capsaicin appears grammatically defective. The technically coherent interpretation is that the second patch is used to reduce or control capsaicin-related side effects.

Claim 4: 7.5% to 10% concentration

Claim 4 is the most commercially relevant dependent claim because Qutenza contains 8% capsaicin.[2] It does not, by itself, cover every 8% capsaicin product. The product would still need to satisfy the patch, reservoir, continuous-delivery, neuropathic-pain, human-treatment, and several-week-relief requirements of claim 1.

Claim 5: capsaicin specifically

Claim 5 eliminates the need to prove that the product contains a broader capsaicin analog. It is narrower in chemical scope but potentially easier to apply to an 8% capsaicin product.

When did Patent 6,239,180 lose U.S. exclusivity?

Patent 6,239,180 expired on November 4, 2018, based on the 20-year term measured from the November 4, 1998 nonprovisional filing date.[1] The patent issued before the expiration date, but issuance in 2001 did not reset the patent term.

Event	Date
Earliest identified priority date	November 4, 1997
U.S. nonprovisional filing	November 4, 1998
Patent issued	May 29, 2001
Ordinary 20-year expiration	November 4, 2018
Current enforceability	Expired

The 1997 priority date is relevant to prior-art analysis but ordinarily does not determine the post-1995 U.S. patent term. The controlling term generally runs from the earliest effective nonprovisional application in the relevant chain.

No current Paragraph IV risk attaches to this patent because an expired patent cannot block an ANDA launch through an ordinary Orange Book patent challenge.

What is the Orange Book status of Patent 6,239,180 and Qutenza?

Qutenza is an FDA-approved 8% capsaicin topical system marketed by Averitas Pharma. The product was originally developed and commercialized through the NeurogesX and later Grünenthal commercial structure. FDA approved Qutenza under NDA 022395 for postherpetic neuralgia and later expanded the product’s use to diabetic peripheral neuropathy of the feet.[2][3]

Qutenza is administered by healthcare professionals. The current product protocol includes:

8% capsaicin topical system;
60-minute application for postherpetic neuralgia;
30-minute application for diabetic peripheral neuropathy of the feet;
pretreatment with a topical anesthetic;
post-treatment cleansing with the supplied cleansing gel.[2]

The product is technically aligned with the concentration and high-dose treatment concept in Patent 6,239,180. Its current commercial protocol does not necessarily satisfy every limitation of claim 3 because the anesthetic step need not be performed with a second anesthetic patch.

Because the patent expired in 2018, any former Orange Book listing for Patent 6,239,180 no longer provides an active patent barrier. FDA regulatory exclusivity and patent exclusivity are separate rights. Expiration of the patent did not automatically terminate the Qutenza NDA, FDA approval, labeling, or regulatory obligations.

Are there Paragraph IV challenges to Qutenza?

A Paragraph IV certification is relevant only where an ANDA applicant seeks approval of a product referencing an NDA with listed patents and asserts that the patents are invalid, unenforceable, or will not be infringed.

For Patent 6,239,180, the practical Paragraph IV issue ended with patent expiration in 2018. A generic applicant could now rely on patent expiration rather than litigate a live claim under this patent.

The more significant regulatory question is whether a proposed competing product would qualify as an ANDA product or require a different FDA pathway. Qutenza is a drug delivered through a topical system, creating potential questions regarding:

dosage-form sameness;
active-ingredient sameness;
delivery-system equivalence;
application time;
concentration;
adhesion;
pharmacokinetic or local exposure equivalence;
labeling and administration by healthcare professionals.

A competing product that cannot demonstrate the required pharmaceutical equivalence may require a 505(b)(2) application rather than a conventional ANDA. That distinction can affect development cost, clinical requirements, labeling strategy, and market-entry timing.

What formulations and delivery systems are protected by the patent?

The patent’s formulation scope is functional and concentration-based. It does not recite a specific solvent, polymer, adhesive, backing, membrane, enhancer, or manufacturing process.

Potentially relevant formulation variables include:

capsaicin particle size;
solvent system;
polymeric matrix;
adhesive composition;
release rate;
patch thickness;
application area;
backing layer;
reservoir architecture;
capsaicin analog selection;
stabilizers and antioxidants.

A later patent directed to a specific adhesive, polymer matrix, capsaicin loading method, patch geometry, or controlled-release profile could remain relevant even after Patent 6,239,180 expired. Patent 6,239,180 does not confer ownership over every later 8% capsaicin patch design.

The patent also does not expressly claim:

a particular capsaicin manufacturing process;
a defined patch size;
a specific application time;
a named anesthetic;
a particular cleansing composition;
a particular indication such as diabetic neuropathy;
a specific packaging configuration.

Those subjects would generally require separate claim language in later patents.

How does Patent 6,239,180 compare with Qutenza’s commercial product?

Issue	Patent 6,239,180	Qutenza
Active	Capsaicin or capsaicin analog	Capsaicin
Concentration	Greater than about 5% to 10%; dependent claim 7.5% to 10%	8%
Delivery	Skin-adherent reservoir patch	8% topical system
Patient	Human	Human
Disease	Neuropathic pain	Postherpetic neuralgia and diabetic peripheral neuropathy of the feet
Anesthesia	Required by claim 2	Used in product protocol
Second anesthetic patch	Required only by claim 3	Not necessarily required
Relief duration	At least several weeks in claim 1	Label supports repeat treatment based on response, with effects persisting for weeks or longer in clinical use
U.S. patent status	Expired November 4, 2018	Product remains FDA-approved

The commercial product strongly corresponds to the patent’s central technical disclosure. That correspondence does not mean the entire Qutenza product is limited to this patent. Commercial products commonly depend on multiple patent families, regulatory protections, trademarks, know-how, supply arrangements, and manufacturing controls.

How strong was the patent estate for high-dose capsaicin therapy?

Patent 6,239,180 was commercially important because it combined three elements that were difficult to avoid in a high-dose capsaicin product:

a patch-based delivery system;
a concentration in the 5% to 10% range; and
prolonged relief after a single administration.

Its strongest practical coverage was directed to an 8% capsaicin patch for neuropathic pain. Claim 4 reinforced that position by expressly covering the 7.5% to 10% range.

The estate was weaker against products that used:

lower concentrations;
creams or gels rather than patches;
non-reservoir delivery systems;
capsaicin analogs outside the claimed concentration;
treatment of non-neuropathic pain;
short-duration dosing;
alternative routes of administration.

The functional duration limitation could also create proof issues. An accused product might match the chemical and device limitations but dispute whether one treatment produces “significant relief” for “at least several weeks” in the claimed patient population.

What patent litigation and settlement issues affect the product?

Patent 6,239,180 is expired, so it cannot support a current injunction against a generic or competing product. A later entrant would instead face potential rights relating to:

improved capsaicin formulations;
patch construction;
adhesive systems;
manufacturing processes;
dosing protocols;
combination treatment with anesthetics;
specific neuropathic-pain indications;
device packaging and application tools.

No current litigation based solely on enforceable claims of Patent 6,239,180 changes the U.S. launch analysis. Any settlement involving later patents would need separate review because the expiration of this patent does not extinguish independent rights in later patent families.

What generic launch risks exist for Qutenza?

The principal risks are regulatory and technical rather than Patent 6,239,180 infringement.

A generic or 505(b)(2) competitor would need to address:

whether the product is pharmaceutically equivalent to Qutenza;
whether its patch has the same active ingredient and dosage form;
whether its release and adhesion characteristics are comparable;
whether the FDA will accept an abbreviated pathway;
whether later unexpired patents cover formulation or manufacturing details;
whether the product can reproduce the required clinical duration;
whether healthcare professionals can apply and remove the patch safely.

The expired patent reduces a major barrier but does not eliminate product-development risk. An 8% patch with a different adhesive or matrix may avoid later formulation patents while creating equivalence, safety, or manufacturing problems.

What is the international patent position?

U.S. Patent 6,239,180 has territorial effect only in the United States. Foreign counterparts require separate analysis by country, including:

European Patent Office validation states;
Canada;
Japan;
Australia;
South Korea;
China;
major Latin American markets.

Patent terms commonly approximate 20 years from the relevant filing date, but national prosecution, supplementary protection certificates, patent-term adjustments, maintenance failures, disclaimers, and local claim amendments can change the result. A U.S. expiration date cannot be automatically applied to foreign family members.

Key Takeaways

U.S. Patent 6,239,180 covers a high-concentration capsaicin or capsaicin-analog patch for prolonged relief of human neuropathic pain.
Claim 1 requires a skin-adherent reservoir patch, continuous skin delivery, a concentration greater than about 5% through 10%, and relief lasting at least several weeks.
Claim 4 specifically covers the 7.5% to 10% concentration range and is directly relevant to Qutenza’s 8% capsaicin system.
Claims 2 and 3 address anesthesia before treatment, with claim 3 requiring a second anesthetic patch.
The patent expired on November 4, 2018.
It creates no current U.S. Paragraph IV barrier or enforceable patent risk.
Qutenza remains FDA-approved, but its current regulatory status is separate from the expired patent.
Future competitors must analyze later patents covering formulations, patch construction, manufacturing, dosing protocols, and specific indications.
The most realistic competing-product pathway may involve an ANDA or 505(b)(2) application, depending on pharmaceutical and device equivalence.

FAQs

Is an 8% capsaicin patch covered by Patent 6,239,180?

An 8% capsaicin patch falls within the concentration range of claim 4 and likely aligns with the central subject matter of claim 1. The patent, however, expired in 2018, so the coverage has no current U.S. enforcement effect.

Does the patent cover Qutenza’s anesthetic cream?

No. Claim 3 requires a second patch capable of delivering the anesthetic. An anesthetic cream, gel, or injection would not literally satisfy that specific limitation, although claim 2 addresses pretreatment with effective anesthesia more generally.

Can a company launch a competing 8% capsaicin patch without a license to Patent 6,239,180?

In the United States, the expired patent cannot independently require a license. The company must still evaluate later patents, regulatory pathway requirements, trademarks, manufacturing rights, and other contractual restrictions.

Does Patent 6,239,180 cover capsaicin treatment for non-neuropathic pain?

The supplied claims require treatment of neuropathic pain. A product directed solely to arthritis, muscle pain, visceral pain, or another non-neuropathic condition would not satisfy that express disease limitation.

Is Qutenza a biologic subject to biosimilar competition?

No. Qutenza is a small-molecule capsaicin drug delivered through a topical system. A competing product would be evaluated under a generic or other drug-approval pathway, not the biosimilar pathway under the Public Health Service Act.

References

United States Patent and Trademark Office. (2001). U.S. Patent No. 6,239,180, Treatment of neuropathic pain with capsaicin. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2023). Qutenza (capsaicin) topical system, 8%: Prescribing information. Averitas Pharma, Inc.
U.S. Food and Drug Administration. (2020). FDA approves expanded use of Qutenza for diabetic nerve pain. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	240723	⤷ Start Trial
Austria	344023	⤷ Start Trial
Canada	2314326	⤷ Start Trial
Cyprus	1107582	⤷ Start Trial
Germany	69814917	⤷ Start Trial
Germany	69836352	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,239,180

Summary for Patent: 6,239,180